Enzalutamide 40mg
| Product Overview | |
| Generic Name | Enzalutamide 40mg |
| Brand Name(s) | Xtandi® |
| Product Type | Originator Brand |
| Form | 112 Oral film-coated 40mg tablets |
| Strength | 40mg |
| Therapeutic Class | Androgen receptor inhibitor / androgen receptor signalling inhibitor |
| ATC Code | L02BB04 |
| Manufacturing & Regulatory | |
| Manufacturer | Astellas Pharma; |
| Country | Japan/US/EU |
| GMP Compliance | PIC/S, WHO |
| COFEPRIS | 010.000.6097.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 36 months |
| Storage | 20–25°C |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes, typically available as a lot/batch CoA |
| SDS | Upon Request, not publicly posted |
Description
Enzalutamide is an oral androgen receptor inhibitor used for prostate cancer, including castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence
